1 |
add. analysis BCR-ABL quantitative |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
2 |
BEI T-LGL, sequencing STAT4 |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
3 |
CBFβ-MYH11 quantitative A-type |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
4 |
Clonal T-cell receptor TCR-Beta |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
5 |
Clonal T-cell receptor TCR-Gamma |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
6 |
confirmation sequencing after HRM |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
7 |
detection KIT D816V |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
8 |
detection t(8:13) |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
9 |
Fast Test AML FAB M2 M3 M4 |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
10 |
Follow up BCR-ABL, quant. |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
11 |
Follow up BCR-ABL, quant. Bonemarrow |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
12 |
fragment analysis and sequencing ex9 of CALR |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
13 |
genotyping JAK-2, Exon12 |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
14 |
IDH2 (Isocitrate dehydrogenase 2) |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
15 |
IGVH fragment length analysis in suspected B-cell clonality |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
16 |
inv16 t(16;16) AML FAB M4 (CBFβ-MYH11) |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
17 |
JAK2 search for mutations Ex.12-15 (HRM) |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
18 |
JAK2 V617F quantitative PCR |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
19 |
Mikrodeletion 4q12 (FIP1L1-PDGFRA PCR) |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |
20 |
Minimal residual disease JAK2 V617F |
Molecular Hemato-Oncology |
Molecular Hemato-Oncology |